Other clinical studies on various IRDs, such as choroideremia caused by mutations in the CHM gene, have reported significant improvements in visual acuity and retinal sensitivity, using AAV2-REP1 administered under the retina, indicating a promising therapeutic path for this condition as well. Here, CHM is linked to choroideremia.